ArticleReviews in cardiovascular medicine2025
Prognostic Value of Pericoronary Adipose Tissue Attenuation After Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis and Obstructive Coronary Artery Disease.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to examine the prognostic value of pericoronary adipose tissue (PCAT) attenuation at three months after transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis (AS) and obstructive coronary artery disease (CAD). Methods: This retrospective study included 226 patients with both obstructive CAD and AS who underwent TAVR. PCAT attenuation was measured three months post-TAVR using coronary computed tomography angiogram (CCTA) images. Univariable and multivariable Cox regression analyses were conducted to evaluate the association between PCAT attenuation and major adverse cardiac events (MACEs). Results: Of the 226 patients, 37 experienced MACEs during a median follow-up period of 1.5 years. High PCAT attenuation was significantly associated with MACEs (-65.3 Hounsfield units (HU) vs. -71.6 HU; Conclusions: PCAT attenuation was independently associated with the risk of MACEs in post-TAVR patients with obstructive CAD and AS, suggesting the potential utility of PCAT attenuation for risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.